BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 7, Issue 9
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (11251)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.
Item 
Count 
PDF687
WORD352
HTML4262
Figures (1-1)506
Tables (1-1)489
 Sum=6296
Featured Article
The chart showing Browse series, Download series.
Item 
Count 
Browse605
Download1168
 Sum=1773
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse1364
Download1818
 Sum=3182
May 28, 2015 (publication date) through Feb 27, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. May 28, 2015; 7(9): 1184-1191
Published online May 28, 2015. doi: 10.4254/wjh.v7.i9.1184
Intermediate hepatocellular carcinoma: How to choose the best treatment modality?
Giovan Giuseppe Di Costanzo, Raffaella Tortora
Giovan Giuseppe Di Costanzo, Raffaella Tortora, Department of Transplantion, Liver Unit, Cardarelli Hospital, 80131 Napoli, Italy
Author contributions: Both authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; both authors also contributed to drafting the article, revising it critically for important intellectual content and final approval of the version to be published.
Conflict-of-interest: The authors have declared no conflicts of interest.
Correspondence to: Giovan Giuseppe Di Costanzo, Department of Transplantation, Liver Unit, Cardarelli Hospital, Via A Cardarelli 9, 80131, Naples, Italy. ggdicostanzo@libero.it
Fix: +39-081-7472208
Received: September 5, 2014
Peer-review started: September 6, 2014
First decision: September 28, 2014
Revised: January 18, 2015
Accepted: February 9, 2015
Article in press: February 11, 2015
Published online: May 28, 2015
Processing time: 257 Days and 1.8 Hours
Core Tip

Core tip: Intermediate stage, or stage B according to Barcelona Clinic Liver Cancer classification, of hepatocellular carcinoma (HCC) comprises a heterogeneous population with different tumor burden and liver function. This heterogeneity is confirmed by the large variability in treatment and survival, the choice of the best treatment in the patient with intermediate stage HCC is a difficult task. A multisciplinary evaluation of each intermediate stage HCC patient is recommended for planning the best therapeutic strategy and this review was aimed to discuss about the existing evidences regarding this topic. Due to the heterogeneity of intermediate HCC, the use of different therapies (combination treatment) is likely the best choice in most of the cases offering the opportunity of a treatment tailored to the single patient.
Write to the Help Desk
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345